Rafael Holdings, Inc. (RFL)
| Market Cap | 48.11M |
| Revenue (ttm) | 697,000 |
| Net Income (ttm) | -39.78M |
| Shares Out | 24.67M |
| EPS (ttm) | -1.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,046 |
| Open | 1.750 |
| Previous Close | 1.800 |
| Day's Range | 1.720 - 1.950 |
| 52-Week Range | 1.290 - 2.500 |
| Beta | 1.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 27, 2024 |
About RFL
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently un... [Read more]
Financial Performance
In 2024, Rafael Holdings's revenue was $637,000, an increase of 128.32% compared to the previous year's $279,000. Losses were -$34.41 million, 1734.2% more than in 2023.
Financial StatementsNews
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol® Cyclo™ Upon completion of our proposed merger with Cy...
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need Our proposed merger with ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeu...
Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries
BOSTON--(BUSINESS WIRE)--Accession Risk Management Group, the parent company of Risk Strategies and One80 Intermediaries comprising North America's ninth largest privately held insurance broker, has c...
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
NEWARK, N.J. & GAINESVILLE, Fla.--(BUSINESS WIRE)--Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreem...
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from t...
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential Strategically focused on generati...
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments Company remains focused on generating shareholder ...
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities Company positions itself to generate value for its stockho...
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medici...
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase our investment by $5 million Since the end o...
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medici...
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medici...
Rafael Holdings Announces up to $5 Million Share Repurchase Program
Announces expanded search for strategic opportunities beyond biopharma Announces expanded search for strategic opportunities beyond biopharma
Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results
NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31...
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022.
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
NEWARK, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced its decision to curtail its early-stage development efforts, including pre-clinical research at the Ba...
Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
NEWARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), a holding company with interests in clinical and early-stage pharmaceutical companies, today reported its financial r...
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancer Clinical program advancement rep...
Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage
NEWARK, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today announced that it has closed on the sa...
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmac...
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmac...
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmac...